ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
ARWR$49.00-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net income (loss) | $13,993 | $(436,349) |
| Adjustments to reconcile net income (loss) to net cash flow from operating activities | ||
| Stock-based compensation | 44,279 | 54,494 |
| Depreciation and amortization | 17,542 | 13,570 |
| (Accretion) amortization of note premiums/discounts | (4,545) | 7,886 |
| Realized loss on investments | — | (80) |
| Non-cash interest expense on liability related to the sale of future royalties | 18,893 | 17,705 |
| Non-cash interest expense on credit facility | 48,774 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (9,841) | — |
| Prepaid expenses and other assets | (22,342) | (1,746) |
| Accounts payable | 21,662 | 2,785 |
| Accrued expenses | 7,956 | 13,086 |
| Deferred revenue | 22,979 | (866) |
| Operating lease, net | (3,417) | 3,880 |
| Other | 3,128 | — |
| Net cash provided by (used in) operating activities | 159,061 | (325,635) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of property and equipment | (15,177) | (117,180) |
| Purchases of investments | (774,616) | (428,611) |
| Proceeds from sales and maturities of investments | 587,880 | 348,642 |
| Net cash used in investing activities | (201,913) | (197,149) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from the exercises of stock options | 3,476 | 2,166 |
| Proceeds from the issuance of common stock, net of offering costs | — | 429,265 |
| Proceeds from the sales of future royalties | — | 50,000 |
| Proceeds from the issuance of warrants | 25,000 | — |
| Payments of debt issuance costs | (5,000) | — |
| Proceeds from the issuance of common stock | 241,388 | — |
| Repayments of credit facility | (201,625) | — |
| Proceeds from Visirna credit agreement | 7,098 | — |
| Net cash provided by financing activities | 70,337 | 481,431 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 27,485 | (41,353) |
| Effect of exchange rate on cash, cash equivalents and restricted cash | (377) | (139) |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||
| BEGINNING OF PERIOD | 102,685 | 110,891 |
| END OF PERIOD | $129,793 | $69,399 |
| Supplementary disclosure of cash flows: | ||
| Interest paid | $(19) | $— |
| Income taxes paid | $(81) | $(3,062) |
| Supplemental disclosure of non-cash investing activities: | ||
| Capital expenditures included in accrued expenses | $346 | $6,909 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.